Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Sugen claims compounds that modulate protein kinases and phosphatases

Jan. 30, 2002

MG-98 enters clinical trials in MDS and AML

Jan. 30, 2002

Novel caspase inhibitors identified at Vertex

Jan. 29, 2002

Schering AG and Mologen to develop cell-based therapies

Jan. 29, 2002

Iressa under regulatory review in two major markets for NSCLC

Jan. 29, 2002

Human Genome Sciences submits IND for B-cell-targeting LymphoRad

Jan. 28, 2002

Cell Pathways updates phase IIa program of CP-461 in cancer

Jan. 28, 2002

Tubulin-binding agents from AstraZeneca with antiangiogenic activity

Jan. 25, 2002

FDA approval granted for Eligard 7.5 mg, formerly Leuprogel One-Month Depot

Jan. 25, 2002

Merck's European C225 program progresses as planned despite U.S. setback

Jan. 25, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...